EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21, 2021

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

First Oral SERD Elacestrant Achieves Positive Findings in EMERALD Trial for ER+/HER2– Advanced or Metastatic Breast Cancer
October 21, 2021

Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer experienced a progression-free survival benefit after being treated with elacestrant.

COLOMATE challenge to overcome resistance in metastatic colorectal cancer
October 21, 2021

Takayuki Yoshino, MD, PhD gives his perspective on the COLMATE trial and what it's done to help patients overcome colorectal cancer.

Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
October 21, 2021

Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.

Future Directions in Multiple Myeloma Care: Improvements and Unmet Needs
October 21, 2021

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM
October 21, 2021

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Biennial Mammography Screenings Reduce Breast Cancer Mortality Disparities in Black Populations
October 21, 2021

Investigators compared tradeoffs in breast cancer screening strategies in Black patients vs White patients.

Intravesical BCG Plus Novel IL-15 Superagonist Complex Improves DFS in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
October 20, 2021

Patients with Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer experienced a disease-free survival benefit when treated with intravesical Bacillus Calmette-Guerin and a novel IL-15 superagonist complex .

FDA Issues Complete Response Letter For Narsoplimab as Treatment of HSCT–Associated Thrombotic Microangiopathy
October 20, 2021

The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.